FilingReader Intelligence
Jubilant Pharmova revenue up 8%, profit surges 112%
August 5, 2025 at 06:09 PM UTC•By FilingReader AI
Jubilant Pharmova Limited reported revenue up 8% to INR72,345 million and EBITDA rising 24% to INR12,300 million, achieving a 16.9% margin. Normalised profit surged 112% to INR4,152 million.
Net debt-to-EBITDA improved from 2.5x to 1.1x. The company targets doubled revenues and 23-25% EBITDA margins by 2030.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:JUBLPHARMA•Bombay Stock Exchange
News Alerts
Get instant email alerts when JUBILANT PHARMOVA publishes news
Free account required • Unsubscribe anytime